American Board of Internal Medicine
Residency, Internal Medicine
St. Barnabas Medical Center
Mount Sinai Hospital
A Phase 3 Trial of Pembrolizumab (MK-3475) vs Standard Treatment in Recurrent/Metastatic Head and Neck Cancer
You are being asked to provide any leftover DNA and tumor tissue samples collected in the main study that would routinely be thrown out after the main study is over. Your agreement to give these samples is entirely up to you. Whether or not you decide to participate i...
A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to: Test the safety, tolerability and anti-tumor activity of the research study drug, pembrolizumab (MK-3475) in subjects with recurrent/metastatic head and neck squamous cell cancer. OR Pembrolizumab (MK-3475) with standard treatment chem...
Phase I Study of Cabazitaxel- PF Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to collect information on the safety of Cabazitaxel and to learn how effective Cabazitaxel is in combination with Cisplatin and Fluorouracil in treating your type of cancer. Information from other research studies suggests that Cabazitaxel decreases t...
The goal of this research study is to compare the standard treatment to VTX-2337 added to the standard treatment to see if it helps your ...
A phase Ib dose escalation/randomized phase II, multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma
This study is divided into two parts: The purpose of the first part (phase Ib) of this study is to establish a safe dose range for BYL719 and cetuximab in combination, based on side effects. Once the right dose combination is found, the second part of the study will start. You wi...
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Misiukiewicz during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.